These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12671287)

  • 1. Amyotrophic lateral sclerosis and glutamate.
    Ludolph AC; Meyer T; Riepe MW; Vökel H
    Restor Neurol Neurosci; 1998; 13(1-2):59-67. PubMed ID: 12671287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adverse efects of riluzole (Rilutek) in the treatment of amyotrophic lateral sclerosis].
    Roch-Torreilles I; Camu W; Hillaire-Buys D
    Therapie; 2000; 55(2):303-12. PubMed ID: 10967703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
    Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
    Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Etiological drug therapy for amyotrophic lateral sclerosis].
    Cintas P
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S220-4S227. PubMed ID: 17128115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of transition metals in the pathogenesis of amyotrophic lateral sclerosis.
    Vonk WI; Klomp LW
    Biochem Soc Trans; 2008 Dec; 36(Pt 6):1322-8. PubMed ID: 19021549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up.
    Deda H; Inci MC; Kürekçi AE; Sav A; Kayihan K; Ozgün E; Ustünsoy GE; Kocabay S
    Cytotherapy; 2009; 11(1):18-25. PubMed ID: 19012065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of amyotrophic lateral sclerosis - what is the next step?
    Ludolph AC
    J Neurol; 2000 Dec; 247 Suppl 6():VI/13-8. PubMed ID: 19714403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection.
    Ganel R; Ho T; Maragakis NJ; Jackson M; Steiner JP; Rothstein JD
    Neurobiol Dis; 2006 Mar; 21(3):556-67. PubMed ID: 16274998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis.
    Lederer CW; Torrisi A; Pantelidou M; Santama N; Cavallaro S
    BMC Genomics; 2007 Jan; 8():26. PubMed ID: 17244347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonergic mechanisms in amyotrophic lateral sclerosis.
    Sandyk R
    Int J Neurosci; 2006 Jul; 116(7):775-826. PubMed ID: 16861147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients.
    Iłzecka J; Stelmasiak Z; Solski J; Wawrzycki S; Szpetnar M
    Neurol Sci; 2003 Nov; 24(4):290-2. PubMed ID: 14658053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
    Dib M
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathogenic mechanisms of neurodegenerative diseases: amyotrophic lateral sclerosis].
    Kato AC; Vingerhoets FJ; Magistris MR; Kuntzer T; Burkhard PR
    Rev Med Suisse; 2006 May; 2(64):1152-4, 1156-7. PubMed ID: 16734186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase.
    Tolosa L; Mir M; Asensio VJ; Olmos G; Lladó J
    J Neurochem; 2008 May; 105(4):1080-90. PubMed ID: 18182045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid from amyotrophic lateral sclerosis patients preferentially elevates intracellular calcium and toxicity in motor neurons via AMPA/kainate receptor.
    Sen I; Nalini A; Joshi NB; Joshi PG
    J Neurol Sci; 2005 Aug; 235(1-2):45-54. PubMed ID: 15936037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is prostaglandin E(2) a pathogenic factor in amyotrophic lateral sclerosis?
    Almer G; Kikuchi H; Teismann P; Przedborski S
    Ann Neurol; 2006 Jun; 59(6):980-3. PubMed ID: 16619237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies.
    Bruijn LI; Cudkowicz M
    Expert Rev Neurother; 2006 Mar; 6(3):417-28. PubMed ID: 16533145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered in-vitro and in-vivo expression of glial glutamate transporter-1 following exposure to cerebrospinal fluid of amyotrophic lateral sclerosis patients.
    Shobha K; Vijayalakshmi K; Alladi PA; Nalini A; Sathyaprabha TN; Raju TR
    J Neurol Sci; 2007 Mar; 254(1-2):9-16. PubMed ID: 17254611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Animal models of amyotrophic lateral sclerosis].
    Yamanaka K
    Rinsho Shinkeigaku; 2007 Nov; 47(11):934-7. PubMed ID: 18210840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.